The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma

Nadiye Akdeniz; Mehmet Küçüköner; Muhammet Ali Kaplan; Zuhat Urakçı; Oğur Karhan; Halis Yerlikaya; Şahin Laçin; Halil Kömek; Abdurrahman Işıkdoğan

doi:10.5798/dicletip.705798

The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma

Abstract

Objective: 18-Fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) is one of the most valuable imaging types and tumor metabolic volume is another parameter that can be obtained from PET-CT. Our primary objective is to evaluate the effect of PET-CT metabolic parameters on survival in patients with malignant pleural mesothelioma (MPM). Methods: A total of 29 patients with MPM had been evaluated with 18F-FDG PET-CT between January 2016 and December 2017. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), standardized uptake values (SUVmax) and TLG/liver SUVmean values were calculated. Also, effects of these parameters on survival rates were evaluated. Results: Histological subtypes of the disease were determined as epithelioid (n=24), biphasic (n=3), sarcomatoid (n=2). Median overall survival was 255 days (21-903). Median MTV was 225 cm³ (10-1879), median TLG was 1056 g/ml*cm³ (36-18927), median SUVmax was 7.7 (1.5-20) and TLG/liver SUVmean ratio was 561.2 (14.9-8113.7). Sensitivity and specificity for MTV 113 cut-off value were 86.4% and 85.7%, respectively. Determined cut-off value for TLG was 419.5, sensitivity and specificity of the value were 81.8% and 85.7%, respectively. Additionally, determined cut-off value for TLG/liver SUVmean ratio was 107.4, the rate of sensitivity and specificity for this value were 95.5% and 71.4%, respectively. The patients with higher MTV, TLG and TLG/liver SUVmean had worse survival rate. Conclusion: We confirmed significant association between MTV, TLG and TLG/liver SUVmean values and patients survival. These promising PET derived parameters can be used for evaluating treatment response and prognosis in MPM.

Keywords

Malignant pleural mesothelioma,survival,FDG PET/CT

References

1. Chapman A, Mulrennan S, Ladd B, Muers MF. Population-based Epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 2008;63:435-9.
2. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J ClinOncol 1998;16:145-52.
3. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ.Factorspredictive of survivalamong 337 patientswithmesotheliomatreatedbetween 1984 and 1994 bythecancerandLeukemiaGroup B. Chest 1998; 113:723-31.
4. Nowak AK, Armato SG, Ceresoli GL, et al. Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. Lung Cancer 2010;70:1-6.
5. Abakay A, Komek H, Abakay O, et al. Relationship between 18 FDG PET-CT findings and survival of 177 patients with malignant pleural mesothelioma. Eur Rev Med PharmacolSci 2013;17:1233-41.
6. Francis RJ, Byrne MJ, van der Schaaf AA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007;48:1449-58.
7. Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging 2014;41:1113-22.
8. Tanrıkulu Ç, Abakay Ö, Sezgi C, et al. Value of a new inflammatory parameter in malignant pleural mesotheliomaprognosis. Dicle Med J 2013; 40:241-4.

9. Nowak AK, Francis RJ, Phillips MJ, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010;16:2409-17.
10. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann ThoracSurg 1999;68:1799-804.
11. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J ThoracCardiovascSurg 1998;115:310-7.
12. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J ClinOncol 1993;11:1172-8.
13. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999;40:1241-5.
14. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005;49:27-32.
15. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J ThoracCardiovascSurg 2006;132:763-8.
16. Gerbaudo VH, Mamede M, Trotman-Dickenson B, Hatabu H, Sugarbaker DJ. FDG PET/CT patterns of treatment failure of malignant pleuralmesothelioma: relationship to histologic type, treatment algorithm, and survival. Eur J Nucl Med MolImag 2011;38:810-21.
17. Kitajima K, Doi H, Kuribayashi K, al. Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. Eur J Radiol 2017;86:176-83.
18. Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Annals SurgOncol 2010;17:2787-94.
19. Incerti E, Broggi S, Fodor A, et al. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. Eur J Nucl Med Mol Imaging 2018;45:2071-8.
20. Zucali PA, Lopci E, Ceresoli GL, et al. Prognostic and predictive role of [18F] fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. Cancer Med 2017;6:2287-96.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Nadiye Akdeniz This is me
Türkiye

Mehmet Küçüköner This is me
Türkiye

Muhammet Ali Kaplan This is me
Türkiye

Zuhat Urakçı This is me
Türkiye

Oğur Karhan This is me
Türkiye

Halis Yerlikaya This is me
Türkiye

Şahin Laçin This is me
Türkiye

Halil Kömek This is me
Türkiye

Abdurrahman Işıkdoğan This is me
Türkiye

Publication Date

March 17, 2020

Submission Date

July 14, 2019

Acceptance Date

January 7, 2020

Published in Issue

Year 2020 Volume: 47 Number: 1

DOI

https://doi.org/10.5798/dicletip.705798

IZ

https://izlik.org/JA25GC26TT

Cite

RIS / Bibtex

APA

Akdeniz, N., Küçüköner, M., Kaplan, M. A., Urakçı, Z., Karhan, O., Yerlikaya, H., Laçin, Ş., Kömek, H., & Işıkdoğan, A. (2020). The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma. Dicle Medical Journal, 47(1), 16-23. https://doi.org/10.5798/dicletip.705798

AMA

1.Akdeniz N, Küçüköner M, Kaplan MA, et al. The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma. Dicle Medical Journal. 2020;47(1):16-23. doi:10.5798/dicletip.705798

Chicago

Akdeniz, Nadiye, Mehmet Küçüköner, Muhammet Ali Kaplan, et al. 2020. “The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma”. Dicle Medical Journal 47 (1): 16-23. https://doi.org/10.5798/dicletip.705798.

EndNote

Akdeniz N, Küçüköner M, Kaplan MA, Urakçı Z, Karhan O, Yerlikaya H, Laçin Ş, Kömek H, Işıkdoğan A (March 1, 2020) The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma. Dicle Medical Journal 47 1 16–23.

IEEE

[1]N. Akdeniz et al., “The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma”, Dicle Medical Journal, vol. 47, no. 1, pp. 16–23, Mar. 2020, doi: 10.5798/dicletip.705798.

ISNAD

Akdeniz, Nadiye - Küçüköner, Mehmet - Kaplan, Muhammet Ali - Urakçı, Zuhat - Karhan, Oğur - Yerlikaya, Halis - Laçin, Şahin - Kömek, Halil - Işıkdoğan, Abdurrahman. “The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma”. Dicle Medical Journal 47/1 (March 1, 2020): 16-23. https://doi.org/10.5798/dicletip.705798.

JAMA

1.Akdeniz N, Küçüköner M, Kaplan MA, Urakçı Z, Karhan O, Yerlikaya H, Laçin Ş, Kömek H, Işıkdoğan A. The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma. Dicle Medical Journal. 2020;47:16–23.

MLA

Akdeniz, Nadiye, et al. “The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma”. Dicle Medical Journal, vol. 47, no. 1, Mar. 2020, pp. 16-23, doi:10.5798/dicletip.705798.

Vancouver

1.Nadiye Akdeniz, Mehmet Küçüköner, Muhammet Ali Kaplan, Zuhat Urakçı, Oğur Karhan, Halis Yerlikaya, Şahin Laçin, Halil Kömek, Abdurrahman Işıkdoğan. The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma. Dicle Medical Journal. 2020 Mar. 1;47(1):16-23. doi:10.5798/dicletip.705798